UnknownPHASE2, PHASE3NCT04219241

Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.

Studying Huntington disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Azidus Brasil
Principal Investigator
Joyce Macedo, MD
Azidus Brasil Scientific Research and Development Ltda
Intervention
Cellavita-HD(biological)
Enrollment
35 enrolled
Eligibility
21-65 years · All sexes
Timeline
20202022

Study locations (1)

Collaborators

Cellavita Pesquisa Científica Ltda

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04219241 on ClinicalTrials.gov

Other trials for Huntington disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington disease

← Back to all trials